Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in Metastatic Breast Cancer
NCT02544997Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Sep 2015
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poziotinib in breast cancer, sponsored by Samsung Medical Center. Primary endpoint: Progression-Free Survival at 1 year. Started Sep 2015; status: completed.
02
Drugs
poziotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02544997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544997.